Gefitinib and erlotinib inhibit the activation of EGFR-mediated PI3K/Akt/mTOR in A549, A549-gefitinib-resistant, KRAS-mutant H358, and H441 cells, leading to lung cancer cell apoptosis [56,57]. Here, KRAS is linked to lung carcinoma.